Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of nucresiran in ATTR amyloidosis with cardiomyopathy
MOH_2025-08-24_014294Phase 3Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jun 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nucresiran in transthyretin amyloidosis (ATTR) (3 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Composite of mortality and cardiovascular morbidity. Started Jun 2025; status: recruiting.
02
Drugs
nucresiran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on MOH_2025-08-24_014294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-08-24_014294.